Spotlight Correspondence

Leukemia (2005) 19, 2333–2334. doi:10.1038/sj.leu.2403994; published online 20 October 2005

Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al

R G Piazza1, V Magistroni1, A Franceschino2 and C Gambacorti-Passerini1,3

  1. 1S. Gerardo Hospital, University of Milano Bicocca, Monza, Italy
  2. 2Section of Hematology, S. Gerardo Hospital, Monza, Italy
  3. 3Department of Oncology, McGill University, Montreal, Canada

Correspondence: Professor C Gambacorti-Passerini, University of Milano Bicocca, Department of Internal Medicine, Via Cadore 48, 20052, Monza, Italy. Tel/Fax: + 39 039 233-3539; E-mail: carlo.gambacorti@unimib.it

Received 30 June 2005; Accepted 19 September 2005; Published online 20 October 2005.

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

NEWS AND VIEWS

New-age drug meets resistance

Nature News and Views (19 Jul 2001)

Extra navigation

.

naturejobs

natureproducts


ADVERTISEMENT